BMO Capital Markets’s latest rating for CTMX stock

CytomX Therapeutics Inc’s recently made public that its CEO McCarthy Sean A. unloaded Company’s shares for reported $42175.0 on Mar 19 ’24. In the deal valued at $2.09 per share,20,223 shares were sold. As a result of this transaction, McCarthy Sean A. now holds 524,481 shares worth roughly $1.12 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, BELVIN MARCIA sold 12,795 shares, generating $26,684 in total proceeds. Upon selling the shares at $2.09, the SVP, Chief Scientific Officer now owns 168,579 shares.

Before that, Landau Jeffrey B sold 6,562 shares. CytomX Therapeutics Inc shares valued at $13,685 were divested by the Chief Business Officer at a price of $2.09 per share. As a result of the transaction, Landau Jeffrey B now holds 110,060 shares, worth roughly $0.24 million.

BMO Capital Markets downgraded its CytomX Therapeutics Inc [CTMX] rating to a Market perform from a an Outperform in a research note published on November 14, 2022; the price target was decreased to $2.60 from $3. A number of analysts have revised their coverage, including Wedbush’s analysts, who decreased its forecast for the stock in early July from “an Outperform” to “a Neutral”. Piper Sandler also remained covering CTMX and has decreased its forecast on July 07, 2022 with a “Neutral” recommendation from previously “an Overweight” rating. Mizuho revised its rating on July 07, 2022. It rated CTMX as “a Neutral” which previously was an “a Buy”.

Price Performance Review of CTMX

On Tuesday, CytomX Therapeutics Inc [NASDAQ:CTMX] saw its stock fall -0.47% to $2.14. CytomX Therapeutics Inc shares have risen nearly 38.06% since the year began. Nevertheless, the stocks have risen 44.59% over the past one year. While a 52-week high of $2.86 was reached on 03/04/24, a 52-week low of $1.04 was recorded on 02/13/24. SMA at 50 days reached $1.91, while 200 days put it at $1.58. A total of 0.33 million shares were traded, compared to the trading of 2.85 million shares in the previous session.

Levels Of Support And Resistance For CTMX Stock

The 24-hour chart illustrates a support level at 2.09, which if violated will result in even more drops to 2.04. On the upside, there is a resistance level at 2.17. A further resistance level may holdings at 2.20. The Relative Strength Index (RSI) on the 14-day chart is 51.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 44.74%. Stochastics %K at 52.37% indicates the stock is a holding.

How much short interest is there in CytomX Therapeutics Inc?

A steep rise in short interest was recorded in CytomX Therapeutics Inc stocks on Mar 15, 2024, growing by 2.23 million shares to a total of 3.53 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 1.3 million shares. There was a rise of 63.17%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 5.25% of the overall stock float, the days-to-cover ratio (short ratio) rose to 1.97.

Most Popular